Trial
NCT04361253
Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Brigham and Women's Hospital
Collaborators
—
Condition
COVID
Intervention
High-Titer COVID-19 Convalescent Plasma (HT-CCP)
Why stopped
Futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-13